Pre-Filled Pen
Research use onlyAndarine S4 40mg / 1.5mL
VAT included. Shipping calculated at checkout.
In stock
- ≥99% purity
- HPLC & LC-MS analysed
- Stabilised formula
- The world's first brand of peptides in a pen
Secure delivery
Secure delivery with FedEx within 1–2 business days after payment confirmation
Payment methods
- Bank transfer
What is Andarine S4?
Andarine (S4) is a selective androgen receptor modulator (SARM) that was originally developed in preclinical programmes exploring tissue-selective androgen receptor activation in muscle and bone. The compound was one of the first SARMs described in the scientific literature and remains among the most studied molecules in this class.
In animal models, Andarine showed partial agonist activity at the androgen receptor, with comparatively high selectivity for muscle and bone tissue and a weaker effect on the prostate. For this reason it is used as a reference compound in research on tissue-selective androgen signalling, muscle wasting models and bone mineral density.
Mechanism of action of Andarine S4:
Andarine S4 binds to androgen receptors in muscle and bone tissue, where in experimental studies it activated gene programmes associated with protein synthesis and mineral density. Unlike classical steroidal androgens, preclinical data indicated a smaller effect on tissues such as the prostate, and the molecule is not a substrate for aromatisation to estrogen.
The molecule has a relatively short half-life in animal pharmacokinetic studies, a property that researchers take into account when designing experimental timelines and sampling schedules.
Findings from preclinical studies of Andarine S4:
The following effects have been reported in laboratory and animal studies:
- Preservation of lean muscle mass in rodent models of androgen deficiency or immobilisation;
- Changes in muscle strength and muscle density parameters in animal models;
- Effects on bone mineral density and bone strength in ovariectomised rat models;
- Changes in body composition measurements in experimental settings;
- Tissue selectivity at the androgen receptor compared with steroidal androgens;
- Supplied as a stabilised liquid formulation in a pen format for consistent laboratory handling.
These properties make Andarine S4 a frequently used reference compound in laboratory research on androgen receptor selectivity in muscle and bone tissue. Its safety profile in humans has not been established.
Comparison of Andarine S4 with other SARMs
Andarine (S4) was one of the first SARMs characterised and is known in the research literature for its partial agonist profile, moderate potency and relatively short half-life. It is often compared to Ostarine (MK2866), Ligandrol (LGD-4033) and S23, occupying an intermediate position between these compounds in terms of receptor activity.
Compared to Ostarine, Andarine showed stronger effects on muscle parameters in some animal models, but it has also been associated with reversible visual disturbances in published reports – one of the most distinctive aspects of S4. Ostarine has been studied more extensively in human clinical trials.
Compared to Ligandrol, Andarine has a lower binding potency and a shorter duration of action. LGD-4033 produced larger changes in lean mass in published studies, while S4 has mainly been characterised in preclinical models of muscle preservation and bone density.
Compared to S23, Andarine showed less suppression of endogenous testosterone in animal studies, together with a more moderate anabolic activity. S23 is a full agonist with more pronounced effects on the hypothalamic-pituitary-gonadal axis in preclinical research.
Specifications and storage of Andarine S4:
Content: 40mg Andarine S4 in 1.5ml solution.
Total quantity in pen: 150 units
Store refrigerated and protected from light. For laboratory research use only; not for human consumption.
Reported adverse effects of Andarine S4:
Published preclinical and early research reports have described the following observations:
- Changes in colour perception (yellowish tint) and night vision, reported as reversible;
- Suppression of endogenous testosterone in animal models;
- Variability in androgenic responses between models.
The safety profile of Andarine S4 is still under investigation. This product is intended for research use only.












